283 related articles for article (PubMed ID: 37927462)
1. Features of the immunosuppressive tumor microenvironment in endometrial cancer based on molecular subtype.
Zhang C; Wang M; Wu Y
Front Oncol; 2023; 13():1278863. PubMed ID: 37927462
[TBL] [Abstract][Full Text] [Related]
2. Immune disorder in endometrial cancer: Immunosuppressive microenvironment, mechanisms of immune evasion and immunotherapy.
Zhan L; Liu X; Zhang J; Cao Y; Wei B
Oncol Lett; 2020 Sep; 20(3):2075-2090. PubMed ID: 32782525
[TBL] [Abstract][Full Text] [Related]
3. Nanosized drug delivery systems modulate the immunosuppressive microenvironment to improve cancer immunotherapy.
Yan WL; Lang TQ; Yuan WH; Yin Q; Li YP
Acta Pharmacol Sin; 2022 Dec; 43(12):3045-3054. PubMed ID: 36050519
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors for recurrent endometrial cancer.
Mutlu L; Harold J; Tymon-Rosario J; Santin AD
Expert Rev Anticancer Ther; 2022 Mar; 22(3):249-258. PubMed ID: 35176955
[TBL] [Abstract][Full Text] [Related]
5. Potential applications of nanoparticles for tumor microenvironment remodeling to ameliorate cancer immunotherapy.
Bai Y; Wang Y; Zhang X; Fu J; Xing X; Wang C; Gao L; Liu Y; Shi L
Int J Pharm; 2019 Oct; 570():118636. PubMed ID: 31446027
[TBL] [Abstract][Full Text] [Related]
6. Immune Environment and Immunotherapy in Endometrial Carcinoma and Cervical Tumors.
Lainé A; Gonzalez-Lopez AM; Hasan U; Ohkuma R; Ray-Coquard I
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046702
[TBL] [Abstract][Full Text] [Related]
7. Bibliometric and visualized analysis of the top-100 highly cited articles on immunotherapy for endometrial cancer.
Zheng W; Wu Y; Wang Y; Cheng J; Shen W
Medicine (Baltimore); 2023 Jul; 102(27):e34228. PubMed ID: 37417594
[TBL] [Abstract][Full Text] [Related]
8. Immune evasion in esophageal squamous cell cancer: From the perspective of tumor microenvironment.
Li R; Huang B; Tian H; Sun Z
Front Oncol; 2022; 12():1096717. PubMed ID: 36698392
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in endometrial cancer: rationale, practice and perspectives.
Cao W; Ma X; Fischer JV; Sun C; Kong B; Zhang Q
Biomark Res; 2021 Jun; 9(1):49. PubMed ID: 34134781
[TBL] [Abstract][Full Text] [Related]
10. Identification of molecular subtypes premised on the characteristics of immune infiltration of endometrial cancer.
Liu C; Zhang Y; Hang C
Ann Transl Med; 2022 Mar; 10(6):337. PubMed ID: 35433941
[TBL] [Abstract][Full Text] [Related]
11. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.
Oura K; Morishita A; Tani J; Masaki T
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071550
[TBL] [Abstract][Full Text] [Related]
12. The role and participation of immune cells in the endometrial tumor microenvironment.
Dey DK; Krause D; Rai R; Choudhary S; Dockery LE; Chandra V
Pharmacol Ther; 2023 Nov; 251():108526. PubMed ID: 37690483
[TBL] [Abstract][Full Text] [Related]
13. Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology.
Rousset-Rouviere S; Rochigneux P; Chrétien AS; Fattori S; Gorvel L; Provansal M; Lambaudie E; Olive D; Sabatier R
Biomedicines; 2021 Jun; 9(6):. PubMed ID: 34199461
[TBL] [Abstract][Full Text] [Related]
14. The role of an immune signature for prognosis and immunotherapy response in endometrial cancer.
Meng Y; Yang Y; Zhang Y; Yang X; Li X; Hu C
Am J Transl Res; 2021; 13(2):532-548. PubMed ID: 33594308
[TBL] [Abstract][Full Text] [Related]
15. How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review.
Maiorano BA; Maiorano MFP; Cormio G; Maglione A; Lorusso D; Maiello E
Front Oncol; 2022; 12():844801. PubMed ID: 35494078
[TBL] [Abstract][Full Text] [Related]
16. Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?
Gargiulo P; Della Pepa C; Berardi S; Califano D; Scala S; Buonaguro L; Ciliberto G; Brauchli P; Pignata S
Cancer Treat Rev; 2016 Jul; 48():61-8. PubMed ID: 27362548
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors in endometrial cancer.
Gómez-Raposo C; Merino Salvador M; Aguayo Zamora C; García de Santiago B; Casado Sáenz E
Crit Rev Oncol Hematol; 2021 May; 161():103306. PubMed ID: 33839243
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy resistance in esophageal cancer: Possible mechanisms and clinical implications.
Fang P; Zhou J; Liang Z; Yang Y; Luan S; Xiao X; Li X; Zhang H; Shang Q; Zeng X; Yuan Y
Front Immunol; 2022; 13():975986. PubMed ID: 36119033
[TBL] [Abstract][Full Text] [Related]
19. Immune targets in the tumor microenvironment treated by radiotherapy.
Ozpiskin OM; Zhang L; Li JJ
Theranostics; 2019; 9(5):1215-1231. PubMed ID: 30867826
[TBL] [Abstract][Full Text] [Related]
20. The circadian rhythm key gene
Wu G; Ren H; Hu Q; Ma H; Chen H; Zhou L; Xu K; Ding L
Front Immunol; 2023; 14():1115809. PubMed ID: 37275880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
